A61K 2239/53
Liver
A61K2239/53 (Liver) appears on 82 US grants and 205 published applications in this corpus.
Search patents in A61K- Granted patents
- 82
- Published applications
- 205
- Assignees
- 138
- Inventors
- 488
- Latest grant
- 4 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1994 | 1 | 0 |
| 1995 | 0 | 0 |
| 1996 | 1 | 0 |
| 1997 | 0 | 0 |
| 1998 | 1 | 0 |
| 1999 | 0 | 0 |
| 2000 | 1 | 0 |
| 2001 | 1 | 1 |
| 2002 | 14 | 1 |
| 2003 | 0 | 2 |
| 2004 | 1 | 2 |
| 2005 | 0 | 3 |
| 2006 | 1 | 3 |
| 2007 | 0 | 2 |
| 2008 | 0 | 1 |
| 2009 | 0 | 1 |
| 2010 | 0 | 1 |
| 2011 | 1 | 2 |
| 2012 | 0 | 1 |
| 2013 | 2 | 2 |
| 2014 | 0 | 4 |
| 2015 | 3 | 5 |
| 2016 | 1 | 5 |
| 2017 | 1 | 10 |
| 2018 | 6 | 8 |
| 2019 | 1 | 6 |
| 2020 | 4 | 15 |
| 2021 | 1 | 17 |
| 2022 | 4 | 22 |
| 2023 | 9 | 27 |
| 2024 | 9 | 25 |
| 2025 | 9 | 18 |
| 2026 | 10 | 21 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Compositions and methods regarding engineered and non-engineered γδ T-cells for treatment of solid tumors4 Aug 2026US 12,698,340 B2Adicet Therapeutics, Inc.
- CAR-T cell compositions, methods of use thereof9 Jun 2026US 12,649,774 B2Augusta University Research Institute, Inc.
- Armed dual CAR-T compositions and methods for cancer immunotherapy2 Jun 2026US 12,643,933 B2Simcere Innovation, Inc.
- GPC3 CAR-T cell compositions and methods of making and using the same19 May 2026US 12,630,597 B2Eutilex Co., Ltd.
- Bispecific antibody and use thereof19 May 2026US 12,630,652 B2Keymed Biosciences (Chengdu) Co., Ltd.
- Car-t cell compositions, methods of use thereof1 Oct 2026US 2026/0297160 A1Augusta University Research Institute, Inc.
- Gene-edited natural killer cells27 Aug 2026US 2026/0250634 A1Crispr Therapeutics AG
- Gpc3 binding molecules20 Aug 2026US 2026/0242507 A1Kite Pharma, Inc.
- Recombinant immune cell-based cell therapeutic agent for treating cancer via polyclonal expansion of tumor-infiltrating t cell in tumor6 Aug 2026US 2026/0224615 A1Korea Advanced Institute of Science and Technology
- Chimeric antigen receptor targeting gpc-3 and immune cells expressing such for therapeutic uses30 Jul 2026US 2026/0216241 A1Crispr Therapeutics AG
Most cited
By later US patents
- Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy109US 5,830,464 AFordham University · 1998
- Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes64US 6,017,540 AFordham University · 2000
- Treatment of primary and metastatic neoplastic diseases with HSP70-peptide complexes57US 6,403,095 B1Fordham University · 2002
- Prevention of primary and metastatic neoplastic diseases with GP96-peptide complexes41US 6,436,404 B1Fordham University · 2002
- Prevention of primary and metastatic neoplastic diseases with hsp90-peptide complexes40US 6,447,780 B1Fordham University · 2002